The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry

X. G. L. V. Pouwels, S. M. E. Geurts, B. L. T. Ramaekers, F. Erdkamp, B. E. P. J. Vriens, K. N. A. Aaldering, A. J. van de Wouw, M. W. Dercksen, T. J. Smilde, N. A. J. B. Peters, J. M. van Riel, M. J. Pepels, J. Heijnen-Mommers, M. A. Joore, V. C. G. Tjan-Heijnen, M. de Boer*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)82-89
Number of pages8
JournalActa Oncologica
Volume59
Issue number1
DOIs
Publication statusPublished - 2 Jan 2020

Keywords

  • Eribulin
  • breast neoplasms
  • matching
  • genetic matching
  • relative effectiveness
  • EXPANDED ACCESS PROGRAM
  • EFFICACY
  • MESYLATE
  • SAFETY
  • CAPECITABINE
  • MONOTHERAPY
  • MULTICENTER
  • TOXICITY

Cite this